Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.

Moderna details plans on how it will make enough of its coronavirus vaccine, and Sosei is using structure-based design technology to target a SARS-CoV-2 non-strucural protein. Meanwhile, the industry in India faces up to lockdown. 

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.

A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher;  Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.

Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.

The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda. 

The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.